Avoid common mistakes on your manuscript.
In the October publication (vol 33, no 5, p 884), Heiko Alfke mentions the “Study of Tamoxifen and Raloxifene” [1]. I am sure that this should have read, “Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial” [2]—both of course with the acronym STAR.
In the United Kingdom, the latter (and the ASTRAL trial) seem to have had a huge impact on clinical practice. I find it curious that other trials, such as the EVAR and the Vertebroplasty trials, have had so little impact. Surely, all are imperfect. Do we interpret trials to suit our prejudices?
References
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (NSABP) (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741
Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, Braam B, Huysmans FT, Schultze Kool LJ, Rutten MJ, Doorenbos CJ, Aarts JC, Rabelink TJ, Plouin PF, Raynaud A, van Montfrans GA, Reekers JA, van den Meiracker AH, Pattynama PM, van de Ven PJ, Vroegindeweij D, Kroon AA, de Haan MW, Postma CT, Beutler JJ (2009) Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 150(12):840–848
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dyer, J. Erratum Regarding Renal Artery Stenting. Cardiovasc Intervent Radiol 34, 254 (2011). https://doi.org/10.1007/s00270-011-0115-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-011-0115-0